Перевести на Переведено сервисом «Яндекс.Перевод»

DURECT

Country
USA
Краткое название
DURECT
Headquarters
10260 Bubb Road
Members of the board

Felix Theeuwes, D.Sc.,
Chairman and Chief Scientific Officer
James E. Brown, D.V.M,.
President and Chief Executive Officer
Michael H. Arenberg,
Senior Vice President, Corporate and Business Development
David J. Ellis, M.D., Ph.D.,
Vice President, Clinical and Regulatory Affairs
John W. Gibson, M.S.,
Vice President, Birmingham Operations and Principal Scientist
Steve Helmer,
Vice President, Chief Patent Counsel
Matthew J. Hogan,
Chief Financial Officer
Judy Joice,
Vice President, Operations and Corporate Quality Assurance
Jian Li,
Vice President, Finance and Corporate Controller
WeiQi Lin, M.D., Ph.D.,
Vice President, R&D Business Development & Principal Scientist
Andrew R. Miksztal, Ph.D,
Vice President, Pharmaceutical Research and Development
Su IL Yum, Ph.D.,
Executive Vice President, Pharmaceutical Systems R&D and Principal Engineer

Categories medicine
Cardiology, Neurology
Stage of the project
Production
Disease
Multiocular sclerosis, Hypertensive disease
Ticker
DRRX
Current owners

Felix Theeuwes, D.Sc.,
Chairman and Chief Scientific Officer
James E. Brown, D.V.M.,
President and Chief Executive Officer
Simon X. Benito,
Director
Dr. Terrence F. Blaschke,
Director
Michael D. Casey,
Director
David R. Hoffmann,
Director, Lead Independent Director
Armand P. Neukermans Ph.D.,
Director
Jon S. Saxe,
Director

Assets
297.7200
Technology
Technologies, Pharmaceuticals, Chemistry